Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria

Part of paid clinical trials in Denver, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT01701583
Phase
PHASE4
Status
Completed

Conditions

  • Chronic Urticaria

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Omalizumab — DRUG
    Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.

Study Details

This study looks at changes in cell proteins in people with chronic hives treated with omalizumab.

Key Dates

Start date
Apr 30, 2013
Status verified
Nov 2020
Primary completion
Apr 30, 2016
Completion
Oct 31, 2017

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Omalizumab
    Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.

Primary Outcome Measure

Change in the Basophil Proteome [ Time Frame: Baseline through week 13 ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado HospitalDenverColorado80045-

Find similar trials in Denver, CO

By research site
University of Colorado Hospital· Denver, CO